These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 24866422)

  • 1. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined pharmacotherapy for TS and OCD.
    Hawkridge S; Stein DJ; Bouwer C
    J Am Acad Child Adolesc Psychiatry; 1996 Jun; 35(6):703-4. PubMed ID: 8682749
    [No Abstract]   [Full Text] [Related]  

  • 5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
    Grados MA; Riddle MA
    J Clin Child Psychol; 2001 Mar; 30(1):67-79. PubMed ID: 11294079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
    Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
    J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome in adults with obsessive-compulsive disorder.
    Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
    Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do all obsessive-compulsive disorder subtypes respond to medication?
    Grados M; Riddle MA
    Int Rev Psychiatry; 2008 Apr; 20(2):189-93. PubMed ID: 18386211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach.
    Uguz F
    Braz J Psychiatry; 2015; 37(4):334-42. PubMed ID: 26692431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of antipsychotics in the treatment of obsessive compulsive disorder.
    Fineberg NA; Gale TM; Sivakumaran T
    J Psychopharmacol; 2006 Jan; 20(1):97-103. PubMed ID: 16204331
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.